Bone Historical Financial Ratios
| BBLG Stock | USD 0.85 0.01 1.16% |
Bone Biologics is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 1.8, PTB Ratio of 0.43 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Bone Biologics Corp financial condition quickly.
Bone |
About Bone Financial Ratios Analysis
Bone Biologics CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Bone Biologics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Bone financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Bone Biologics history.
Bone Biologics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Bone Biologics Corp dividend as a percentage of Bone Biologics stock price. Bone Biologics Corp dividend yield is a measure of Bone Biologics stock productivity, which can be interpreted as interest rate earned on an Bone Biologics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Bone Biologics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Bone Biologics' PB Ratio is most likely to increase significantly in the upcoming years. The Bone Biologics' current EV To Operating Cash Flow is estimated to increase to 0.48, while Operating Cash Flow Per Share is projected to decrease to (2.85).
| 2024 | 2025 (projected) | Payables Turnover | 0.001341 | 0.001274 | Days Of Inventory On Hand | 368.2 | 327.29 |
Bone Biologics fundamentals Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Book Value Per Share | (268.48) | 152.92 | 126.54 | 11.05 | 2.3 | 2.41 | |
| Free Cash Flow Yield | (0.005748) | (0.0676) | (3.01) | (8.03) | (2.89) | (2.75) | |
| Operating Cash Flow Per Share | (8.37) | (28.57) | (75.89) | (36.32) | (2.72) | (2.85) | |
| Free Cash Flow Per Share | (8.37) | (28.57) | (75.89) | (36.32) | (2.72) | (2.85) | |
| Roic | 0.42 | (0.17) | 0.29 | (3.24) | (1.21) | (1.15) | |
| Net Income Per Share | (35.78) | (37.46) | 14.81 | (34.01) | (4.83) | (5.07) | |
| Pocfratio | (173.98) | (14.8) | (0.33) | (0.12) | (0.35) | (0.36) | |
| Interest Coverage | (2.27) | (2.51) | (0.83) | (1.37) | (1.23) | (1.29) | |
| Pfcf Ratio | (173.98) | (14.8) | (0.33) | (0.12) | (0.35) | (0.36) | |
| Income Quality | 0.23 | 0.76 | 2.4 | 1.07 | 1.0 | 0.7 | |
| Roe | 0.13 | (0.24) | 0.12 | (3.08) | (2.1) | (2.0) | |
| Ev To Operating Cash Flow | (201.44) | (9.37) | 1.78 | 0.19 | 0.46 | 0.48 | |
| Pe Ratio | (40.71) | (11.29) | 1.7 | (0.13) | (0.19) | (0.2) | |
| Ev To Free Cash Flow | (201.44) | (9.37) | 1.78 | 0.19 | 0.46 | 0.48 | |
| Earnings Yield | (0.0246) | (0.0886) | 0.59 | (7.52) | (5.13) | (4.88) | |
| Net Debt To E B I T D A | (2.88) | (4.62) | (14.21) | (6.31) | 0.79 | 0.83 | |
| Tangible Book Value Per Share | (268.48) | 152.92 | 126.54 | 11.05 | 2.3 | 2.41 | |
| Shareholders Equity Per Share | (268.48) | 152.92 | 126.54 | 11.05 | 2.3 | 2.41 | |
| Graham Net Net | (268.48) | 152.92 | 100.01 | 8.34 | 1.94 | 2.04 | |
| Enterprise Value Over E B I T D A | (2.88) | (34.97) | (104.24) | (3.83) | 0.45 | 0.47 | |
| Price Earnings Ratio | (40.71) | (11.29) | 1.7 | (0.13) | (0.19) | (0.2) | |
| Price To Operating Cash Flows Ratio | (173.98) | (14.8) | (0.33) | (0.12) | (0.35) | (0.36) | |
| Price To Free Cash Flows Ratio | (173.98) | (14.8) | (0.33) | (0.12) | (0.35) | (0.36) | |
| Ebt Per Ebit | 2.21 | 1.46 | 0.41 | 0.95 | 1.74 | 1.65 | |
| Effective Tax Rate | (4.68E-4) | (8.78E-4) | (9.94E-4) | 1.47 | 1.32 | 1.39 |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.